Release of our first CSR Report!
We’re excited to announce the publication of our first CSR Report!
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
HTL Biotechnology is proud to support National Biomedicines manufacturing Day, which will take place on June 5, 2025.
HTL Biotechnology CEO François Fournier spoke to leading Korean media DongA Ilbo, reaffirming Korea’s strategic importance and the strong, long-standing ties with Korean customers.
We are excited to share that HTL Biotechnology is present at the AMWC 2025 in Monaco.
Feel the difference with HTL inside
Feel the difference with HTL inside
A global company with a heart in Brittany
HTL Biotechnology is the pioneer in the development and sustainable production of pharmaceutical grade biopolymers, used to develop life-changing treatments for millions of patients worldwide.
Backed by 30 years of expertise, we now work with more than 100 clients in 30 countries. In total, over 400 million syringes of hyaluronic acid have been safely used since 2006.
As the market leader in pharmaceutical grade biopolymers for medical use, we work every day to :